Processa Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Processa Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 5 completed early-phase tilt top decile by trial count

Processa Pharmaceuticals: 9 sponsored US clinical trials, 1 recruiting.

Processa Pharmaceuticals sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Tumor Gastric, with 1 trials.

Top-decile sponsor footprint

Processa Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

NCT06568692
COMPLETED Phase 2

Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis

NCT05270460
COMPLETED Phase 1

A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors

NCT04861987
TERMINATED Phase 2

A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

NCT04800562
COMPLETED Phase 2

A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

NCT03698864
COMPLETED Phase 1

RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

NCT03189914
COMPLETED Phase 1

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

NCT02030067
TERMINATED Phase 2

Open Label Extension Study of HT-100 in Patients With DMD

NCT01978366
TERMINATED Phase 1

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy

NCT01847573

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 5

Therapeutic Areas

Tumor Gastric 1
Metastatic Bladder Cancer 1
TNBC - Triple-Negative Breast Cancer 1
HER2-Negative Breast Cancer 1
Advanced Cancer 1
Breast Cancer 1
Solid Tumor 1
Refractory Cancer 1

What is open in the Processa Pharmaceuticals pipeline

1 recruiting of 9 indexed (11% open); 5 completed (56%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Tumor Gastric (1 trial), 7 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Processa Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Processa Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Processa Pharmaceuticals4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
Processa Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Processa Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Processa Pharmaceuticals page

9 registered trials is a research-attention snapshot, not an endorsement of Processa Pharmaceuticals or any single study.

  • 1 of Processa Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Tumor Gastric is the condition Processa Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Tumor Gastric trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Processa Pharmaceuticals pipeline card: 9 registered trials from official public datasets.Report a data error.